[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remimazolam-besylate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remimazolam-besylate":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640506","phase-3-effect-of-remimazolam-sedation-on-outcomes-of-mechanically-ventilated-patients-in-the-icu-100640506",false,"NCT07596589","Effect of Remimazolam Sedation on Outcomes of Mechanically Ventilated Patients in the ICU","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Endotracheal intubation and mechanical ventilation for 24-96 hours before enrollment Expected need for continued invasive ventilation and sedation for at least 24 hours;\n* Target sedation depth on the Richmond Agitation-Sedation Scale (RASS) between 0 and -3;\n* Informed consent obtained from the patient's family\n\nExclusion Criteria:\n\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Severe central nervous system disease (e.g., acute stroke, uncontrolled seizures, or severe dementia) or any other condition that precludes RASS assessment\n* Mean arterial pressure (MAP) \\\u003C 55 mmHg despite intravenous fluid resuscitation and vasopressors\n* Heart rate \\\u003C 50 beats per minute, or second-degree or third-degree atrioventricular block in the absence of a pacemaker\n* Acute myocardial infarction or severe heart failure (New York Heart Association \\[NYHA\\] class IV)\n* Left ventricular ejection fraction \\\u003C 30%\n* Any contraindication or allergy to benzodiazepines\n* Substance dependence, alcohol abuse, or psychiatric\u002Fpsychological disorders. Alcohol abuse was defined as regular consumption of \\> 14 drinks per week (1 drink = 150 mL wine, 360 mL beer, or 45 mL liquor)\n* Acute hepatitis or severe hepatic dysfunction (Child-Pugh class C)\n* Chronic kidney disease with a glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Neuromuscular disease\n* Patients on extracorporeal membrane oxygenation (ECMO)\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The goal of this clinical trial is to evaluate the effect of remimazolam sedation on outcomes of mechanically ventilated ICU patients through a single-center, prospective, randomized controlled, pilot study.",[25,26,27],"Remimazolam Besylate","Mechanically Ventilated ICU Patients","Sedation",[29,30,31],"remimazolam","sedation","ICU","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2025-04-01",{"date":40,"type":19},"2027-01-31",{"name":42,"class":43},"Southeast University, China","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100599624","phase-1-the-impact-of-remimazolam-tosilate-on-oxygenation-and-postoperative-cognitive-function-in-elderly-patients-undergoing-thoracoscopic-lobectomy-100599624","NCT07086911","The Impact of Remimazolam Tosilate on Oxygenation and Postoperative Cognitive Function in Elderly Patients Undergoing Thoracoscopic Lobectomy","The Impact of Tosylate Remimazolam on Oxygenation and Postoperative Cognitive Function in Elderly Patients Undergoing Thoracoscopic Lobectomy","Inclusion Criteria:\n\n* Patients scheduled for thoracoscopic surgery under general anesthesia at the First Affiliated Hospital of Kunming Medical University;\n* Age 65 to 75 years old;\n* BMI18-30 kg\u002Fm ²;\n* ASA grades I to III;\n* There are no contraindications to any related drugs;\n* Both the patient and their family members agreed to participate in this study and signed the informed consent form\n\nExclusion Criteria:\n\n* Patients with severe sinus bradycardia (heart rate \\\u003C50 beats per minute) and atrioventricular block;\n* Respiratory tract infection and the use of non-steroidal anti-inflammatory drugs or hormone drugs within 2 weeks before the operation;\n* Those with central nervous system and psychological disorders;\n* Have taken anticholinergic drugs, anticonvulsants, anti-anxiety drugs, antidepressants, etc. in the past half year;\n* Severe liver and kidney dysfunction and immune system diseases, uncontrolled hypertension and diabetes;\n* History of preoperative radiotherapy and chemotherapy;\n* Patients with communication barriers who are unable to cooperate to complete the test;\n* The OLV \\\u003C 60 min or interim thoracotomy patients;\n* Intraoperative blood loss \\> 1500ml;\n* Patients transferred to the ICU ward after the operation.","65 Years","75 Years",{"count":55,"type":19},150,[57,58],"PHASE1","PHASE2","Background: During thoracoscopic lobectomy in elderly patients, one-lung ventilation (OLV) is a common procedure. However, this process is prone to cause hypoxemia and postoperative cognitive dysfunction (POCD), which seriously affect the postoperative recovery and prognosis of patients. At present, there is still a need for further exploration and optimization of effective anesthetic drugs and regimens to improve intraoperative oxygenation and reduce the occurrence of POCD in such patients. Remimazolam besylate, as a novel anesthetic drug, has not yet had its advantages in thoracoscopic surgery in elderly patients fully clarified. This study is conducted to explore its effects on oxygenation and postoperative cognitive function in this specific surgical setting, so as to provide new references for clinical drug use and improve the perioperative management and postoperative outcomes of elderly patients.\n\nObjective:To mainly investigate the effects of remimazolam besylate on oxygenation and intrapulmonary shunting during one-lung ventilation in elderly patients undergoing thoracoscopic surgery, as well as its impact on postoperative cognitive dysfunction.\n\nResearch Content:The research content includes the observation and evaluation of oxygenation index, shunt fraction, cognitive function status, intraoperative conditions (such as OLV duration, blood loss, etc.),hemodynamic indicators, blood gas analysis indicators, serum indicators, and postoperative recovery status (such as postoperative sedation, pain, adverse reactions, pulmonary complications, hospital stay duration, etc.) in elderly patients undergoing thoracoscopic lobectomy.\n\nResearch Methods:\n\nStudy Design: A randomized controlled study will be adopted. Case Selection: Inclusion Criteria: Patients aged 65-75 years old, with a BMI of 18-30 kg\u002Fm², ASA classification of I-III, no contraindications to related drugs, and consent from the patient and their family to participate in the study and sign the informed consent form, who are scheduled for thoracoscopic surgery under general anesthesia at the First Affiliated Hospital of Kunming Medical University from December 2024 to December 2025, will be selected. Exclusion Criteria: Patients with severe arrhythmias, preoperative respiratory tract infections, central nervous system diseases, hepatic or renal insufficiency, immune system diseases, a history of preoperative radiotherapy or chemotherapy, communication barriers, etc., will be excluded. Exclusion Criteria: Patients with OLV duration less than 60 minutes or conversion to thoracotomy, intraoperative blood loss greater than 1000 ml, and those transferred to the ICU after surgery will be excluded.\n\nGrouping and Anesthesia Methods: Patients will be randomly divided into three groups: Remimazolam Group (R Group), Propofol Group (P Group), and Remimazolam Combined with Propofol Group (C Group), with 50 cases in each group. After anesthesia induction, the three groups will be maintained with different drugs and doses until 10 minutes before the end of the surgery, while remifentanil will be combined, and the infusion rate of the drugs will be adjusted according to the BIS value.\n\nData Collection: Detailed records will be kept of the patient's general information, intraoperative conditions, perioperative cardiovascular reactions, blood gas analysis indicators, serum indicators, as well as postoperative cognitive function assessment, sedation and pain assessment, adverse reactions, and complications.\n\nSample Size Calculation: Based on the oxygenation index at 60 minutes of OLV, which is the primary endpoint, and in combination with relevant literature and statistical requirements, the sample size for each group is calculated to be 58. Considering the dropout and withdrawal rates, the final sample size for each group is determined to be 70.\n\nStatistical Analysis: SPSS 27.0 software will be used. Normal distribution measurement data, non-normal distribution measurement data, and count data will be analyzed using independent sample t-test, Wilcoxon rank-sum test, and chi-square test or Fisher's exact probability method, respectively. A P value less than 0.05 will be considered statistically significant.\n\nTechnical and Feasibility Assurance: Relying on the clinical resources and technical platform of the First Affiliated Hospital of Kunming Medical University, as well as the research team's proficiency in thoracic anesthesia techniques and the operation of related equipment, the smooth conduct of the study will be ensured.",[25,61,62,63],"Thoracoscopic Lobectomy","Oxygenation","Postoperative Cognitive Dysfunction","NOT_YET_RECRUITING","2025-07-17",{"date":67,"type":36},"2025-07-25",{"date":69,"type":19},"2025-08",{"date":71,"type":19},"2026-12",{"name":73,"class":43},"Jinqiao Qian",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":52,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100571510","study-on-the-feelings-of-euphoria-caused-by-remimazolam-during-gastroscopy-and-colonoscopy-and-their-related-factors-100571510","NCT06721195","Study on the Feelings of Euphoria Caused by Remimazolam During Gastroscopy and Colonoscopy and Their Related Factors","A Cross-Sectional Study on Euphoria Induced by Remimazolam During Gastrointestinal Endoscopy and Its Related Factors","ERGE","Inclusion Criteria:\n\n* Adults aged 18 to 65 years, regardless of gender.\n* Patients scheduled for routine painless gastrointestinal endoscopy, including gastroscopy, colonoscopy, or both.\n* ASA physical status classification: I or II.\n* BMI between 18 kg\u002Fm² and 28 kg\u002Fm².\n* Anticipated procedural duration of no more than 30 minutes.\n* Patients who have provided written informed consent after understanding the study purpose, procedures, and potential risks.\n\nExclusion Criteria:\n\n* History of psychiatric disorders such as schizophrenia, bipolar disorder, or personality disorders, or a history of alcohol, stimulant, or other substance abuse.\n* Known allergies or intolerance to any medication used in the study, including remimazolam, sufentanil, or benzodiazepines.\n* Patients requiring complex endoscopic procedures (e.g., ERCP, endoscopic submucosal dissection, endoscopic mucosal resection, or peroral endoscopic myotomy).\n* History of severe hepatic or renal disease.\n* Pregnant or lactating women.\n* Participation in another clinical study within the past three months.\n* Any condition or factor that, in the investigator's judgment, makes the patient unsuitable for participation in the study.",{"count":83,"type":19},305,"1 Day","OBSERVATIONAL","This study aims to investigate the incidence of euphoria induced by remimazolam during gastrointestinal endoscopy and explore its related factors. Gastrointestinal endoscopy, a minimally invasive procedure, often causes discomfort and anxiety for patients. Remimazolam, a short-acting benzodiazepine, is increasingly used for sedation during these procedures due to its rapid onset, short metabolism, and controlled cardiorespiratory effects. This cross-sectional study will evaluate the effect of remimazolam on patient comfort, cooperation, and satisfaction during endoscopy, aiming to optimize sedation protocols and improve clinical outcomes.",[88,25,89],"Euphoria","Gastrointestinal Endoscopy","2024-12-03",{"date":92,"type":36},"2024-12-06",{"date":94,"type":36},"2024-08-01",{"date":96,"type":19},"2024-12-31",{"name":98,"class":43},"Zhangjie Yu"]